Cargando…
Liushen Capsules, a promising clinical candidate for COVID-19, alleviates SARS-CoV-2-induced pulmonary in vivo and inhibits the proliferation of the variant virus strains in vitro
BACKGROUND: Coronavirus disease 2019 (COVID-19) causes a global pandemic and has devastating effects around the world, however, there are no specific antiviral drugs and vaccines for the constant mutation of SARS-CoV-2. PURPOSE: In this study, we evaluted the antiviral and anti-inflammatory activiti...
Autores principales: | Ma, Qinhai, Lei, Biao, Chen, Ruihan, Liu, Bin, Lu, Wencong, Jiang, Haiming, Chen, Zexing, Guo, Xiaowen, Wang, Yutao, Zhang, Lu, Chen, Qiaoyan, Li, Xiaobo, Yang, Zifeng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8972667/ https://www.ncbi.nlm.nih.gov/pubmed/35365215 http://dx.doi.org/10.1186/s13020-022-00598-4 |
Ejemplares similares
-
Investigating the effects of Liushen Capsules (LS) on the metabolome of seasonal influenza: A randomized clinical trial
por: Ma, Qinhai, et al.
Publicado: (2022) -
Corrigendum: Investigating the effects of Liushen Capsules (LS) on the metabolome of seasonal influenza: A randomized clinical trial
por: Ma, Qinhai, et al.
Publicado: (2023) -
Effect of Jinzhen granule on two coronaviruses: The novel SARS-CoV-2 and the HCoV-229E and the evidences for their mechanisms of action
por: Ma, Qinhai, et al.
Publicado: (2022) -
Efficacy and safety of ReDuNing injection as a treatment for COVID-19 and its inhibitory effect against SARS-CoV-2
por: Ma, Qinhai, et al.
Publicado: (2021) -
Oral Liushen pill for patients with COVID‐19: A prospective randomized controlled trial
por: Zhang, Jianping, et al.
Publicado: (2023)